What is Scorpius Holdings Inc?
, through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization.
SCPX · Verdict
Moderate reward · high risk
SCPX's standout is growth; balance sheet and cash flow weigh on the picture.
Based on 88% data coverage
SCPX · Verdict
Rev +43.5% CAGR · earnings -2.2%
Current ratio 0.18
-431% free-cash-flow margin
-526% net margin · -303% ROE
Below average
Model-based scoring. For information only — not financial advice.
, through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. The company is listed on the AMEX in USA, operating in the Healthcare sector, with a market capitalisation of 739.83K.
The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.